ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics today announced the availability of its first commercial assay and research service for the measurement of neurally-derived biomolecules in vivo. The SILK-Aß™ assay refers to the use of stable isotope labeling and tandem mass spectrometry for the measurement of the kinetics, or metabolism, of amyloid-beta. Amyloid-beta is a small peptide implicated as a key mediator of Alzheimer’s disease.
